Sanofi: agreement to acquire Inhibrx
The French healthcare group explains that INBRX-101 could enable the treatment of alpha-1-antitrypsin deficiency, a rare inherited disease that mainly affects the lungs and leads to progressive tissue deterioration.
For each Inhibrx share, Inhibrx shareholders will receive $30 in cash, a five-dollar contingent value right and 0.25 shares in a new publicly listed company that will retain the non-INBRX-101 assets (New Inhibrx).
Sanofi's acquisition of Inhibrx is subject to the demerger transaction leading to the creation of New Inhibrx and other customary closing conditions. Both companies expect to close the transaction in the second quarter of 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction